Home

Remeg Tenger Csavart abl 001 Fajta Közönségesség Boltos

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine  Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry

ABL Bio
ABL Bio

ABL001 strongly inhibited tumor progression of various human gastric... |  Download Scientific Diagram
ABL001 strongly inhibited tumor progression of various human gastric... | Download Scientific Diagram

ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1 |  PNAS
ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1 | PNAS

ABL Bio
ABL Bio

ABL001 by Surya - Abel ABL-001 10"H x 13"W x 13"D | Gamble Home Furnishings
ABL001 by Surya - Abel ABL-001 10"H x 13"W x 13"D | Gamble Home Furnishings

Asciminib (ABL001) | BCR-ABL1 Inhibitor | MedChemExpress
Asciminib (ABL001) | BCR-ABL1 Inhibitor | MedChemExpress

ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.
ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature

Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New  Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming  Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity -  Wiley Online Library
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library

BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML  | BLU Ampersand, Inc.
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.

Molecules | Free Full-Text | Bcr-Abl Allosteric Inhibitors: Where We Are  and Where We Are Going to
Molecules | Free Full-Text | Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine  Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry

Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor  asciminib (ABL001)
Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor asciminib (ABL001)

Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New  Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming  Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity -  Wiley Online Library
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library

ABL-001-Amide-PEG3-acid | Fluorescent Probe | MedChemExpress
ABL-001-Amide-PEG3-acid | Fluorescent Probe | MedChemExpress

ABL Bio
ABL Bio

Efficacy of a combination of TKI and a novel allosteric inhibitor asciminib  in chronic myeloid leukaemia | Faculty of Sciences, Engineering and  Technology | University of Adelaide
Efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia | Faculty of Sciences, Engineering and Technology | University of Adelaide

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine  Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry

ABL001 - GME
ABL001 - GME

GME Antenna Base Universal with 4.5m Coaxial & PL259 - ABL001 - Accessories  | Repco New Zealand
GME Antenna Base Universal with 4.5m Coaxial & PL259 - ABL001 - Accessories | Repco New Zealand

A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two...  | Download Scientific Diagram
A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram

ABL Bio
ABL Bio

Asciminib, Supplier | ABL-001 | CAS 1492952-76-7 | ABL1 inhibitor |  Sun-shinechem
Asciminib, Supplier | ABL-001 | CAS 1492952-76-7 | ABL1 inhibitor | Sun-shinechem